Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27761398 | 1.00 | TSHR (0.47) | — | |
| Methane SCHEMBL27585218 | 0.96 | — | — | |
| SCHEMBL27259142 | 0.96 | TSHR (0.50) | — | |
| SCHEMBL27308161 | 0.96 | TSHR (0.50) | — | |
| SCHEMBL27346657 | 0.96 | TSHR (0.50) | — | |
| SCHEMBL5991 | 0.96 | — | — | |
| SCHEMBL8758797 | 0.92 | — | — | |
| Iodide SCHEMBL5566833 | 0.92 | — | — | |
| Bromide SCHEMBL2124260 | 0.92 | — | — | |
| Ammonia Solution, Strong SCHEMBL7529877 | 0.92 | TSHR (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117148678-A | Chemically amplified positive resist composition and method for forming resist pattern | 信越化学工业株式会社 | 2023-12-01 | — | — | CN | disclosed |
| CN-117148677-A | Chemically amplified positive resist composition and method for forming resist pattern | 信越化学工业株式会社 | 2023-12-01 | — | — | CN | disclosed |
| US-20130165347-A1 | USE OF TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE FOR MUTAGENIC DNA REPAIR TO GENERATE VARIABILITY, AT A DETERMINED POSITION IN DNA | Commissariat L'Energie Atomique Et Aux Energies Alternatives (FR) | 2013-06-27 | — | — | US | disclosed |
| US-20120134928-A1 | MODULATION OF TERMINASE ACTIVITY AT TELOMERES AND DNA DOUBLE-STRAND BREAKS | BAYLOR COLLEGE OF MEDICINE (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012013717-A1 | USE OF TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE FOR MUTAGENIC DNA REPAIR TO GENERATE VARIABILITY, AT A DETERMINED POSITION IN DNA. | INSTITUT PASTEUR (FR) | 2012-02-02 | — | — | WO | disclosed |
| EP-2412806-A1 | Use of terminal deoxynucleotidyl transferase for mutagenic DNA repair to generate variability, at a determined position in DNA | Institut Pasteur (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010132708-A2 | MODULATION OF TERMINASE ACTIVITY AT TELOMERES AND DNA DOUBLE-STRAND BREAKS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20080096770-A1 | Evaluation of the Toxicity of Pharmaceutical Agents | MCGINNIS CLAUDIA | 2008-04-24 | — | — | US | disclosed |
| EP-1807539-A2 | EVALUATION OF THE TOXICITY OF PHARMACEUTICAL AGENTS | Novartis AG (CH) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006050124-A2 | EVALUATION OF THE TOXICITY OF PHARMACEUTICAL AGENTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |